Alluvi, formerly BI 4744, presents a promising advance in obesity treatment. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in research studies, arguably https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/